These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22514793)

  • 41. [Mild forms of multi-infarct dementia: effectiveness of cerebrolysin].
    Vereshchagin NV; Nekrasova EM; Lebedeva NV; Suslina ZA; Solov'ev OI; Piradov MA; Altunina MN
    Sov Med; 1991; (11):6-8. PubMed ID: 1767322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: A prospective, randomized, blinded, and placebo-controlled study.
    Zhang L; Chopp M; Lu M; Zhang T; Winter S; Doppler E; Meier D; Chao L; Eapen A; Pabla P; Gang Zhang Z
    Int J Stroke; 2016 Apr; 11(3):347-55. PubMed ID: 26763925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials.
    Kittner B; De Deyn PP; Erkinjuntti T
    Ann N Y Acad Sci; 2000 Apr; 903():535-41. PubMed ID: 10818549
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
    Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
    Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Zhang D; Dong Y; Li Y; Chen J; Wang J; Hou L
    Biomed Res Int; 2017; 2017():4191670. PubMed ID: 28656143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroprotection in vascular dementia.
    Martínez-Vila E; Murie-Fernández M; Gállego Pérez-Larraya J; Irimia P
    Cerebrovasc Dis; 2006; 21 Suppl 2():106-17. PubMed ID: 16651821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
    Corey-Bloom J
    Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Rivastigmine: a review of its clinical effectiveness].
    Spiegel R
    Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].
    Skvortsova VI; Stakhovskaia LV; Gubskiĭ LV; Shamalov NA; Tikhonova IV; Smychkov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; (Suppl 11):51-5. PubMed ID: 15559222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative study on the clinical features of Alzheimer's disease and vascular dementia].
    Chen X; Zhang ZX; Huang JB; Wen HB
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):122-7. PubMed ID: 15171546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrolysin: a multi-target drug for recovery after stroke.
    Brainin M
    Expert Rev Neurother; 2018 Aug; 18(8):681-687. PubMed ID: 30004268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Facts, myths, and controversies in vascular dementia.
    Román GC
    J Neurol Sci; 2004 Nov; 226(1-2):49-52. PubMed ID: 15537519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W; Stadler CH; Poljakovic Z; Fleet D;
    Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.